NEXT GENERATION ANTIBODY THERAPEUTICS
Improving antibody directed delivery of cargo
iProgen has developed a proprietary and powerful antibody delivery technology platform which can be used to design innovative first-in-class drugs for unmet medical needs.
Our goal is to advance select drug candidates into clinical development to demonstrate the benefits of our technology platform and fostering broad industry adoption.
KEN LEE, MBA
Ken is a biotech entrepreneur with 18 years’ experience in target discovery, preclinical and clinical research management. He received a RAPS-certification for US Regulatory Affairs and Clinical Research Professional designation from the Society of Clinical Research Society. He also received MBA from the Richard Ivey School of Business.
DAVID WOOD, MBA
David is the former Head of Finance and Corporate Development of Celator Pharmaceuticals, Inc. Before joining Celator Pharmaceuticals, Mr. Wood held the position of Managing Director with Cubist Pharmaceuticals (UK) Ltd. Mr. Wood was appointed to National Research Council in February 2008 as a member on its Executive Committee.
MICHAEL J. MACLEOD, LLB
Vice President of Legal
Michael is a Cambridge University educated corporate lawyer, entrepreneur, investor and philanthropist. Previously, he was civil litigator at McCarthy Tetrault and Robertson, Peck, Thompson, Casilio, Vancouver. Formerly, he was also Advisor to the House of Commons Standing Committee on Transport, Ottawa.
PAULA LARIO, PH.D
Director of Protein Engineering
Paula is a veteran protein engineer with two decades of experience. Previously, she led a group of scientists at Zymeworks Inc. leading to the development of novel protein drug engineering technologies that would eventually be licensed to global pharmaceutical companies. She received her Ph. D. from McGill University.
MICHAEL GALLO, PH.D
Michael is founder CEO of Innovative Targeting Solutions Inc. He was formerly the Vice President of Research at Abgenix Inc. and subsequently Amgen British Columbia, Michael oversaw numerous antibody discovery collaborations involving over 100 different targets with collaborators including AstraZeneca, Pfizer, Abbot, Curagen, Milleneum, and Dendreon.
HANS E. HUBER, PH.D
Hans is a retired distinguished scientist from Merck where he spent almost two decades studying biologics and biologics drug delivery technology. He is currently an Associate Director of the Center for Targeted Therapeutics and Translational Nanomedicine at University of Pennsylvania. Hans received his Ph.D. from ETH and completed post-doc at Harvard.
ANTIBODY DRUG CONJUGATE
A critical factor in developing a successful Antibody Drug Conjugate (ADC) is the antibody’s ability to internalize once it binds to the cancer cell’s target-receptor. Although some cancer cell-specific receptors internalize the antibody efficiently following binding (e.g. EGFR2), many cancer cell receptors (e.g. CD20) do not internalize antibodies efficiently.
iProgen has developed a proprietary antibody engineering technology that enhances antibody delivery and internalization. When this technology was applied to ADC, it has shown a significant improvement in in-vivo efficacy in several mouse xenograft models.